,
Congenital myasthenic syndrome (CMS) is an over-durious and odd group of congenital neuromuscular disorders caused by genetic defects that are essential for the integrity of neuromuscular junction.
The company mentions that Argx-119 is the sixth molecule developed to show proof-off-concept through our immunology innovation program, reflecting the strength of its innovation model, where the intensive knowledge of biology and expertise comes together in antibody engineering which is possible.
For such health news, go to RTTNEWS.COM.
The idea and opinion expressed here are the idea and opinion of the author and not necessarily Nasdac, Inc.
